Profile data is unavailable for this security.
About the company
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
- Revenue in SEK (TTM)1.74m
- Net income in SEK-135.74m
- Incorporated2006
- Employees8.00
- LocationKarolinska Development ABTomtebodavagen 23 ASOLNA 171 65SwedenSWE
- Phone+46 852486070
- Websitehttps://www.karolinskadevelopment.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioretec Oy | -1.07tn | -1.07tn | 149.70m | 57.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -57.56 | -- | -77.31 | -- | 70.90 | -- | -128.20 | -- | -- | -- | -- | 16.32 | 21.07 | -21.78 | -- | -- | -- |
| iZafe Group AB | 5.90m | -17.73m | 161.89m | 10.00 | -- | 9.83 | -- | 27.43 | -0.0614 | -0.0614 | 0.0194 | 0.0452 | 0.1757 | 3.44 | 8.15 | 843,000.00 | -52.78 | -57.76 | -73.42 | -72.44 | -106.29 | -287.24 | -300.41 | -630.90 | 0.9122 | -17.45 | 0.0198 | -- | 336.55 | -11.10 | 36.26 | -- | -24.50 | -- |
| Bactiquant A/S | 11.79m | -18.67m | 165.74m | -- | -- | 11.37 | -- | 14.06 | -0.4696 | -0.4696 | 0.2966 | 0.2723 | 0.4656 | 2.69 | 15.14 | -- | -73.73 | -55.41 | -85.85 | -64.53 | -31.80 | -10.94 | -158.37 | -121.81 | 3.26 | -9.70 | 0.1926 | -- | -41.68 | -14.27 | -4.72 | -- | -- | -- |
| Ortivus AB | 75.91m | -24.74m | 168.25m | 34.00 | -- | -- | -- | 2.22 | -0.5583 | -0.5583 | 1.71 | -0.5062 | 1.18 | 6.77 | 16.22 | 2,372,281.00 | -38.46 | -4.62 | -147.30 | -8.65 | 34.79 | 41.27 | -32.59 | -3.55 | 0.4719 | -4.01 | 1.72 | -- | -4.36 | 9.60 | -36.49 | -- | 65.37 | -- |
| BrainCool AB (publ) | 43.62m | -36.85m | 177.70m | 20.00 | -- | 1.00 | -- | 4.07 | -0.1408 | -0.1408 | 0.1666 | 0.4479 | 0.2841 | 1.15 | 2.92 | 2,180,769.00 | -24.00 | -38.93 | -26.22 | -53.10 | 29.86 | 48.00 | -84.48 | -233.83 | 2.29 | -33.11 | 0.00 | -- | 72.05 | 56.50 | 28.13 | -- | 4.34 | -- |
| Micropos Medical AB (publ) | 8.46m | -20.21m | 178.15m | 9.00 | -- | 8.99 | -- | 21.05 | -0.1296 | -0.1296 | 0.0538 | 0.1191 | 0.3797 | -0.0031 | 5.09 | 1,057,905.00 | -90.68 | -74.98 | -115.26 | -98.65 | 100.15 | 87.53 | -238.83 | -670.95 | 4.49 | -70.70 | 0.00 | -- | 133.47 | 36.60 | 7.09 | -- | -- | -- |
| Boule Diagnostics AB | 512.66m | -80.68m | 194.17m | 186.00 | -- | 1.15 | -- | 0.3787 | -2.09 | -2.09 | 13.33 | 4.34 | 1.03 | 4.61 | 4.04 | 2,268,420.00 | -16.14 | -9.09 | -28.43 | -13.28 | 42.88 | 43.62 | -15.74 | -11.16 | 0.7753 | 23.70 | 0.5491 | -- | -2.25 | 2.28 | -1,287.41 | -- | 7.84 | -- |
| Subgen AI AB | 0.00 | -64.18m | 209.86m | 15.00 | -- | -- | -- | -- | -544.10 | -544.10 | 0.00 | -25.11 | 0.00 | -- | -- | 0.00 | -188.83 | -- | -403.12 | -- | -- | -- | -- | -- | -- | -4.46 | -- | -- | -100.00 | -- | 16.86 | -- | -- | -- |
| SciBase Holding AB (publ) | 36.58m | -90.39m | 219.52m | 34.00 | -- | 3.93 | -- | 6.00 | -0.2487 | -0.2487 | 0.0978 | 0.0674 | 0.6648 | 1.29 | 3.23 | 1,143,250.00 | -164.26 | -75.65 | -244.76 | -101.01 | 66.04 | 65.08 | -247.08 | -256.98 | 2.07 | -11.75 | 0.00 | -- | 27.79 | 26.21 | -9.97 | -- | -20.49 | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -35.57m | 225.48m | 21.00 | -- | 1.24 | -- | -- | -4.03 | -4.03 | 0.00 | 15.08 | 0.00 | -- | -- | 0.00 | -19.97 | -- | -24.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 80.11 | -- | -1.65 | -- |
| Integrum AB | 97.00m | -29.85m | 228.79m | 37.00 | -- | 1.21 | -- | 2.36 | -1.37 | -1.37 | 4.50 | 7.26 | 0.5253 | 0.828 | 3.40 | 2,487,052.00 | -16.17 | -3.58 | -17.87 | -4.08 | 75.61 | 83.88 | -30.78 | -6.47 | 1.88 | -- | 0.025 | -- | -12.50 | 27.78 | -864.22 | -- | 103.14 | -- |
| Clinical Laserthermia Systems AB | 21.27m | -38.38m | 238.40m | 16.00 | -- | 3.30 | -- | 11.21 | -5.02 | -5.02 | 1.08 | 2.32 | 0.3208 | 4.58 | 4.84 | 1,329,313.00 | -57.98 | -116.28 | -63.60 | -248.44 | -63.75 | -556.78 | -180.75 | -872.82 | 2.55 | -5.79 | 0.0039 | -- | 127.04 | 67.47 | 40.32 | -- | -- | -- |
| Karolinska Development AB | 1.74m | -135.74m | 243.69m | 8.00 | -- | 0.0789 | -- | 140.21 | -0.4096 | -0.4096 | 0.0052 | 3.28 | 0.0015 | -- | 0.6263 | 217,250.00 | -11.69 | -2.23 | -11.78 | -2.37 | -- | -- | -7,810.36 | -1,161.99 | -- | -1.49 | 0.0017 | -- | -8.74 | -11.49 | -250.41 | -- | -- | -- |
| ContextVision AB | 112.48m | 3.57m | 268.61m | 44.00 | 75.97 | 2.97 | 23.59 | 2.39 | 0.0491 | 0.0491 | 1.58 | 1.25 | 0.9575 | 1.74 | 4.15 | 3,020,009.00 | 3.04 | 30.51 | 3.71 | 45.07 | 97.62 | 98.49 | 3.17 | 28.49 | 4.70 | -- | 0.0847 | -- | -1.15 | 6.51 | -24.60 | 27.25 | -30.69 | -- |
| INIFY Laboratories AB | 20.10m | -61.30m | 288.67m | 34.00 | -- | 2.20 | -- | 14.36 | -1.15 | -1.15 | 0.3729 | 1.73 | 0.1928 | 2.96 | 3.12 | 863,607.90 | -58.78 | -- | -58.78 | -- | 85.20 | -- | -304.93 | -- | -- | -- | 0.00 | -- | 1,000.67 | -- | 3.15 | -- | -- | -- |
| Acarix AB | 6.92m | -52.44m | 314.53m | 8.00 | -- | 8.17 | -- | 45.47 | -0.0472 | -0.0472 | 0.0062 | 0.0343 | 0.1196 | 0.1667 | 2.77 | 864,750.00 | -90.68 | -74.33 | -102.27 | -86.47 | 86.15 | 82.37 | -757.98 | -1,298.77 | 7.93 | -805.72 | 0.00 | -- | -0.6249 | 27.28 | 14.97 | -- | -- | -- |
Data as of Feb 09 2026. Currency figures normalised to Karolinska Development AB's reporting currency: Swedish Krona SEK
3.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 30 Dec 2025 | 5.43m | 2.03% |
| Handelsbanken Fonder ABas of 31 Dec 2025 | 1.51m | 0.57% |
| Skandia Investment Management ABas of 28 Nov 2025 | 1.13m | 0.42% |
| SEB Funds ABas of 31 Dec 2025 | 1.06m | 0.40% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 249.49k | 0.09% |
| Skandia Fonder ABas of 28 Nov 2025 | 43.90k | 0.02% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
